Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

D. Bouros*, N. Bachlitzanakis**, J. Kottakis†, P. Pfister*, V. Polychronopoulos†*, E. Papadakis†, S. Constantopoulos†*, M. Froudarakis*, L. Sichletidis§, N. Siafaska*

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. D. Bouros, N. Bachlitzanakis, J. Kottakis, P. Pfister, V. Polychronopoulos, E. Papadakis, S. Constantopoulos, M. Froudarakis, L. Sichletidis, N. Siafaska.

ABSTRACT: A total of 132 adult asthmatics who were symptomatic on 500 μg day⁻¹ inhaled beclomethasone dipropionate (BDP) were studied in an open-label randomized, parallel group, 12 week, clinical trial.

The addition of 12 μg formoterol fumarate solution aerosol (pressurized metered dose inhaler) b.i.d. to BDP at a dose of 500 μg day⁻¹ was compared with a higher dose of 1,000 μg day⁻¹ BDP.

Mean morning premedication peak expiratory flow rate (PEF) during the final week of treatment (primary end-point) increased in both groups compared to baseline. The estimated treatment difference of 20.4 L.min⁻¹ (95% confidence interval 3.2–37.6) after 12 weeks of treatment was statistically significant (p=0.05) in favour of the formoterol/BDP group. The overall mean morning premedication PEF for the entire treatment period was higher in the formoterol/BDP group (p=0.002). The overall number of puffs of rescue medication and asthma symptom scores were less in the formoterol/BDP group (p<0.01). Safety and tolerability evaluations were satisfactory in both groups.

In conclusion, the results suggest that the addition of formoterol fumarate to the existing dose of an inhaled corticosteroid should be considered as an alternative to increasing the dose of inhaled corticosteroid in the inadequately controlled asthmatic.


There is a tendency to introduce the option of the regular addition of a long-acting β₂-agonist on existing corticosteroid doses in milder asthmatics earlier than previously proposed. This is also reflected in evolving international guidelines for asthma management [1–2].

This, in the light of the ongoing debate concerning the regular use of β₂-agonists and their potential detrimental effects [3–6], generates the need for experimental studies properly designed to evaluate efficacy and to assess benefit/risk ratio of the suggested regimen.

Limited data are currently available. Previous work by GREENING et al. [7] and WOOLCOCK et al. [8] suggested that the regular addition of salmeterol xinofoate to inhaled beclomethasone dipropionate (BDP) at existing doses ranging 400–1000 μg-day⁻¹ resulted in better asthma control than increasing the dose of BDI. Work recently reported on formoterol delivered via a dry powder inhaler (DPI), is also in support of the proposed option [9].

It was therefore hypothesized that adding formoterol to a relatively low dose of an inhaled corticosteroid, in patients still presenting with symptoms, could have similar results to those attained by increased doses of corticosteroids.

To test this hypothesis, a multicentre, randomized, open-label study was conducted using a population of patients still presenting with symptoms despite a daily dose of 500 μg inhaled BDP. In these patients, the administration of 12 μg formoterol fumarate aerosol solution (from a pressurized metered dose inhaler (pMDI)) given as a combined regimen with 250 μg BDP aerosol (pMDI) twice daily, was compared with that of BDP aerosol given at a dose of 500 μg twice daily. This comparison was undertaken over a 12-week period.

Methods

Protocol

This was a randomized, open-label, between-patient clinical study, which was performed in 11 centres in Greece between July 1995 and November 1996. Ethics Committee approvals for each centre, and Regulatory Authority approval for the protocol and informed consent document were secured as required. All patients provided informed consent prior to initiation of any study procedure. A run-in period of 2 weeks, for patients who were previously on treatment with inhaled BDP aerosol at a constant dose of 500 μg daily for at least 1 month, facilitated the establishment of eligibility for subsequent randomization, and served as the baseline for the analyses. Following this run-in period, eligible patients were randomized in a blinded fashion to receive either formoterol fumarate aerosol 12 μg
b.i.d. followed by BDP aerosol 250 μg b.i.d. or monotherapy with BDP aerosol 500 μg b.i.d. for a period of 3 months. During this comparative treatment period, patients returned to the clinic after 4, 6, 8 and 12 weeks for assessment and lung function testing.

At the initial screening (visit 1), β₂-agonists and other anti-asthma medication were removed (except BDP). Patients were provided with salbutamol pMDI (Aerolin®: 100 μg puff⁻¹, GlaxoWellcome, London, UK) to be used for rescue purposes on an "as needed" basis. A spacer device (Optihaler®; Healthscan Inc., Cedar Grove, NJ, USA) was provided for use with the inhaled steroid only, as required by current guidelines [1-2]. At visit 2, randomized patients were requested to discontinue use of their own BDP pMDI, and BDP pMDI (Becotide®: 250 μg puff⁻¹, GlaxoWellcome) was provided to all. In addition, formoterol pMDI (Foradil®: 12 μg puff⁻¹, Novartis, Switzerland) was provided to patients randomized thereafter.

Peak expiratory flow rate (PEF) (best of three measurements using a mini-Wright® peak-flow meter), daytime symptoms (0-4 scale: 0 = no symptoms - unrestricted activity; 4 = symptoms at rest, routine activity affected, rescue medication does not control symptoms well), night time symptoms (0-4 scale: 0 = no symptoms - unrestricted after. Switzerland) was provided to patients randomized there- after. Patients were provided with salbutamol pMDI (Aerolin®: 100 μg puff⁻¹, GlaxoWellcome, London, UK) to be used for rescue purposes on an "as needed" basis. A spacer device (Optihaler®; Healthscan Inc., Cedar Grove, NJ, USA) was provided for use with the inhaled steroid only, as required by current guidelines [1-2]. At visit 2, randomized patients were requested to discontinue use of their own BDP pMDI, and BDP pMDI (Becotide®: 250 μg puff⁻¹, GlaxoWellcome) was provided to all. In addition, formoterol pMDI (Foradil®: 12 μg puff⁻¹, Novartis, Switzerland) was provided to patients randomized thereafter.

All patients were asked to measure PEF at the same time in the morning and in the evening, and always prior to the administration of study medication. Any usage of salbu- tamol rescue within 6 h prior to a PEF measurement was also noted in the patient diary. Patients that made use of more than eight actuations per day of rescue salbutamol, for >2 consecutive days, were instructed to immediately contact their centre's investigator for assessment and ini- tiation of appropriate therapy. The patient remained in the study only in the case of a short additional course of an oral corticosteroid. Addition of any other anti-asthmatic medication was considered as development of an exclusion criterion, and constituted sufficient reason for discontinuation of the particular patient from the study. However, patients that were discontinued from the study, for reasons as outlined above, were subsequently included in the exploratory analysis of the results. In addition, all adverse experiences were noted, by each investigator, in the appro- priate section of the clinical record form (CRF). Serious adverse experiences were reported to the Regulatory Auth- orities within the required expedited time-lines. Finally, lung function was assessed spirometrically (forced expir- atory volume in one second (FEV1) and forced vital capacity (FVC)) during clinic visits, following the ATS guidelines for spirometry [10].

**Patients**

A total of 159 patients, ≥18 yrs old, were enrolled in the study. Patients were subsequently randomized to study treatment, if they fulfilled the following inclusion criteria: a symptom score (day and night) of two or greater on at least 4 of the 7 days during the second week of the run-in period, FEV1 before administration of an inhaled agonist 40-85% of the predicted normal for the patient [11], and a reversibility test with 200 μg salbutamol demonstrating an increase in FEV1 of at least 15% from baseline value [1-2]. Finally, patients were required to have been using inhaled BDP aerosol for a least 1 month prior to enrolment, and at a constant daily dose of 500 μg.

Patients were excluded from participation for the following reasons; if they presented evidence of other clini- cally significant diseases, pregnant or lactating women, patients on β-blocker therapy or with hypersensitivity to sympathomimetic amines, those who were considered unable to comply with the study protocol and patients who had received a short course with an oral corticosteroid in the 6 weeks prior to enrolment, or more than three oral corticosteroid short courses during the year prior to enrolment.

### Statistical analysis

**Efficacy.** The primary objective of this study was to compare the effect of the two treatment regimens on lung function. To achieve this, a confirmatory analysis was carried out on a mean morning premedication PEF measured during the final 7 days of treatment (i.e. week 12 of treatment). Consequently for this analysis, only those patients who had completed the whole treatment period were included. Mean morning PEF was considered using analysis of covariance to estimate treatment contrasts. The baseline value calculated from the last seven days of the run-in period was fitted as a covariate. In addition to the estimate of the treatment difference, its 95% confidence interval (CI) was calculated. An exploratory analysis was carried out on morning and evening PEF during the final 7 days before each monthly examination on asthma scores, rescue medication used, premedication FEV1 measured at the clinic at 4, 8 and 12 weeks, and on the number of premature discontinuations. An analysis of covariance was performed to estimate the treatment contrasts and confidence intervals as above for the overall mean morning PEF, overall mean evening PEF, and the premedication FEV1 measured at the clinic. Asthma scores and rescue medication for the randomized treatment period were analysed using the test of van ELTEREN [12] stratified by centre using a mean score per patient for each variable. Finally, the number of premature discontinuations was considered descriptively. The sample size was estimated in order to detect a difference of 25 L-min⁻¹ using an estimated standard deviation of 48 L-min⁻¹. Therefore, it was considered that ~60 evaluable patients per treatment group would give the study a power of 80% at the 5% significance level.

**Safety.** All patients randomized to treatment were in- cluded in the consideration of safety. This was assessed by the monitoring of adverse experiences. No formal statisti- cal analysis was undertaken. Adverse experiences were summarized by World Health Organisation (WHO) class using two definitions as follows: 1) all adverse experi- ences; and 2) all adverse experiences considered by the investigator to be possible, probably or highly probably related to trial medication.
Results

From a total of 159 patients initially enrolled in the study, 134 were randomized to treatments. Of these 134 patients, 69 were randomized to receive formoterol 12 mg b.i.d. plus BDP 250 mg b.i.d., and 65 were randomized to receive BDP 500 mg b.i.d. (table 1). Accordingly, 25 patients were not randomized, as they did not present the required symptoms that would have qualified them for the set-up in the treatment that the study foresaw, and/or because they did not meet the strict reversibility "eligibility" criterion. Both groups were sufficiently matched as to demographic and baseline characteristics. Immediately after randomization, two patients did not return for scheduled examinations. Thus, 132 patients presented evaluable data. A total of 124 patients completed the trial, of which 122 presented with evaluable data for the confirmatory analysis (mean morning premedication PEF during the final 7 days of treatment). There were 10 premature discontinuations, four in the formoterol/BDP group and six in the higher BDP group. Two premature discontinuations (one in each group) were due to asthma deterioration that led to the development of an exclusion criterion (not allowed add-on therapy). One patient became pregnant during the course of the study and was discontinued. Five patients did not return for a scheduled visit (three on BDP and two on formoterol/BDP), including one patient in the higher BDP group who withdrew consent early in the study.

Peak expiratory flow

Morning premedication PEF increased in both the group of patients that received formoterol/BDP and the group of patients that received BDP alone, compared to baseline values. Confirmatory analysis carried out on the mean morning premedication PEF, measured during the final 7 days of the 12-week treatment period, demonstrated a treatment effect of 20.36 L min⁻¹ in the group of patients that received formoterol/BDP (p=0.021, 95% CI 3.162–37.560) over the group of patients that received BDP only (fig. 1).

Asthma symptom scores

Asthma symptom scores as recorded in the morning (for the previous night), and as recorded in the evening (for the evening premedication). Morning asthma symptom scores as recorded in the morning (for the previous night), and as recorded in the evening (for the evening premedication).
previous day), decreased in both groups of patients compared to baseline. For the overall period, the difference between groups was again in favour of the group of patients that received formoterol plus BDP; day overall \( p = 0.001 \), night overall \( p < 0.001 \) (fig. 4).

**Rescue medication**

The number of puffs of rescue medication (salbutamol) taken during the day and the evening/night, as recorded in the patients’ diary, decreased in both groups of patients compared to baseline. For the overall period, the difference was again in favour of the group of patients that received formoterol plus BDP; day overall \( p < 0.001 \), night overall \( p = 0.003 \) (fig. 5).

**Spirometry**

Premedication FEV1, measured and recorded at each “monthly” clinic visit, also increased in both groups of patients compared to baseline, but the difference between them was statistically significant at week 8. This was in favour of the administration of formoterol plus BDP (p<0.05) (fig. 6).

**Premature discontinuations**

There were a total of 10 premature discontinuations; four in the formoterol/BDP group and six in the higher dose BDP group. Two of them were caused by asthma deterioration (one in each treatment group). This deterioration led to additional treatment (e.g. theophylline), which in turn constituted an exclusion criterion (reason for discontinuation from the study).

**Adverse experiences**

Monitoring of adverse experiences (AEs) did not reveal differences between treatments. Both treatments were well tolerated. There were 74 AEs reported in the group of patients that received formoterol plus BDP, and 102 AEs in the group of patients that received higher dose BDP, irrespective of causality (table 2). A total of seven AEs in the formoterol/BDP group and 27 in the higher BDP group were characterized by the reporting investigator as either possibly or probably related to trial medication. However, the majority of AEs were reported as mild in severity. Furthermore, only two patients presented with a serious AE (one in each group of patients). The patient from the group of patients receiving formoterol plus BDP, was hospitalized for sinusitis. The other patient of the group of patients that received the higher dose BDP, required a brief hospitalization for asthma deterioration and was subsequently discontinued from the trial due to the addition of other anti-asthma therapy (not allowed by the protocol).

**Short courses of oral steroids**

A total of 11 patients received treatment with oral corticosteroids during the study. Eight patients belonged to the group that was under treatment with formoterol/BDP, and three in the group that was under treatment with the higher BDP dose. It should be noted that two patients in the formoterol/BDP group and two patients in the higher BDP group were identified, after study completion, as protocol violators. All four had required, and received, a short course with an oral corticosteroid during the run-in period.
of the study. According to the protocol, this was indicative of unstable disease, and constituted an exclusion criterion. Assessed using the Chi-square test, these differences (8 versus 3; 6 versus 1) have significance values of \( p = 0.14 \) and \( p = 0.06 \), respectively.

**Discussion**

These results show that in adult asthmatic patients still presenting with symptoms, the addition of formoterol fumarate solution aerosol 12 mg twice daily to an existing daily dose of 500 mg of inhaled BDP resulted in a greater improvement in lung function and better control of symptoms, when compared to an increase of the inhaled steroid daily dose to 1,000 mg day\(^{-1}\). The safety and tolerability of both regimens did not differ, and was judged as satisfactory.

These results are in agreement with the results from previous work with salmeterol. Both Greening et al. [7] and Woolcock et al. [8] reported improved lung function and better control of symptoms with the regular addition of salmeterol than with an increase in daily doses of BDP from 400–1,000 mg and from 1,000–2,000 mg, respectively.

Table 2. Number and percentage of adverse experiences (AEs) between treatments

<table>
<thead>
<tr>
<th>Trial treatment</th>
<th>Formoterol/BDP</th>
<th>BDP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Causality</td>
<td>AEs %</td>
<td>AEs %</td>
</tr>
<tr>
<td>Not related</td>
<td>54/74 72.79</td>
<td>59/102 57.84</td>
</tr>
<tr>
<td>Unlikely</td>
<td>13/74 17.57</td>
<td>16/102 15.69</td>
</tr>
<tr>
<td>Possible</td>
<td>5/74 6.76</td>
<td>24/102 23.53</td>
</tr>
<tr>
<td>Probable</td>
<td>1/74 1.35</td>
<td>1/102 0.98</td>
</tr>
<tr>
<td>Highly probably</td>
<td>1/74 1.35</td>
<td>2/102 1.96</td>
</tr>
<tr>
<td>Total</td>
<td>74 100</td>
<td>102 100</td>
</tr>
</tbody>
</table>

BDP: beclomethasone dipropionate.
similar to the findings of PAUWELS et al. [9], who showed that whereas the addition of formoterol to low dose of budesonide was a more effective regimen than increasing the dose of budesonide in terms of lung function, symptoms and \( \beta \)-agonist use, is less effective in terms of reducing exacerbations requiring oral steroid use and/or presenting with a significant decrease in PEF.

It has also been suggested in the past that this improved control of symptoms may lead to a “masking” of the underlying decreased asthma control, and this may develop a tendency for more severe exacerbations in subsets of patients [15]. PAUWELS et al. [9] found that the rates of severe and mild exacerbations were reduced by 26 and 40% when formoterol was added to 200 \( \mu \text{g} \text{day}^{-1} \) and 800 \( \mu \text{g} \text{day}^{-1} \) budesonide, respectively. It is believed that these observations are reassuring when the current findings in relation to exacerbations requiring oral corticosteroids are considered.

Another vital question would be whether regular use of formoterol influences lung function or leads to a rebound increase in bronchial responsiveness on discontinuation of therapy and a reduction in bronchodilator effect. The authors’ experience from this study is consistent with previous studies with formoterol that have shown no reduction in lung function, worsening in bronchial responsiveness or reduction in bronchodilator effect [16–19].

Overall, the current investigation into the efficacy and safety of treatment in this 3-month study failed to identify an area of concern with regard to decreased asthma control, and resulting hazard to the patient. However, further investigations should be undertaken. These should be of longer duration, should include different doses of inhaled corticosteroids (both higher and lower) and large numbers of patients. As this study along with the findings of PAUWELS et al [9] tend to indicate that increasing the maintenance dose of inhaled corticosteroids might be a more appropriate initial therapeutic step in the “subset” of patients with repeated severe exacerbations, such future studies should present with sufficient statistical power that will allow for definite conclusions in this vital area of concern.

In conclusion, the addition of formoterol fumarate should be considered as an alternative to increasing the inhaled corticosteroid dose in the inadequately controlled asthmatic.

Acknowledgements. The authors would like to thank the following physicians/research scientists for enrolling patients at their respective centres, and/or their overall important contributions to the successful completion of this study: S. Tzannes, M. Demadi, G. Mathioudakis, A. Chaniotou, G. Blazoyiakkis, C. Trabari and A. Tsakatikas (Athens); P. Christaki, Y. Piegas and E. Vlachoyianni (Thessaloniki); K. Stachouli (Ioannina); N. Charokopos and K. Sypopulos (Patra); K. Kallergis and N. Tzanakis (Crete); and D. Till (Horsham, UK).

References